Thompson Davis & Co’s Neurogene NGNE Stock Holding History

Thompson Davis & Co’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-50	Closed	-$3K	–	768
2018 Q2	$3K	Buy	+50	New	+$13K	0.01%	583

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Thompson Davis & Co's NGNE Position: Q3 2018 in Review

Thompson Davis & Co sold out of Neurogene (NGNE) in Q3 2018, closing a stake of 50 shares — an estimated $3K sold.

Thompson Davis & Co first reported a position in NGNE in Q2 2018 and held it in 1 quarter. The position peaked at $3K in Q2 2018. 45 funds tracked by Wall St. Rank hold NGNE as of Q3 2018.

Thompson Davis & Co reported no remaining Neurogene position as of Q3 2018 after selling out during the quarter.
Thompson Davis & Co sold 50 Neurogene shares in Q3 2018, an estimated $3K.
Thompson Davis & Co first reported a position in Neurogene in Q2 2018 and held it in 1 quarter.
Thompson Davis & Co's Neurogene position peaked at $3K in Q2 2018.
45 funds tracked by Wall St. Rank held Neurogene as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.